There are an estimated 12 million patients with COPD in the United States, where this disease is now the third leading cause of death, claiming close to 140,000 American lives and being responsible for > 700,000 hospitalizations yearly. 1 Worldwide, it is estimated that approximately 3 million deaths are caused by the disease each year. 2 Treatment guidelines for COPD recommend the use of long-acting bronchodilators, either long-acting b 2 -agonists (LABAs) or long-acting anticholinergics, as first-line maintenance therapy and to combine their use as the disease progresses. 3, 4 Inhaled corticosteroids (ICS) are recommended as additional treatment only for those patients with severe airflow limitation at high risk of exacerbations who remain symptomatic after regular use of long-acting bronchodilators. 4, 5 Nevertheless, ICS are widely used across all COPD severities, even among patients with mild disease, with recent surveys reporting treatment with ICS in > 70% to 80% of patients with COPD, which is considerably discrepant with treatment guidelines. 6, 7 Moreover, the modest effectiveness of ICS as an "across the board" treatment for COPD has been debated, particularly in view of their associated increase in the risk of pneumonia. [8] [9] [10] The current general consensus is that ICS are only effective in a subset of patients with COPD.
Recent research has focused on a precision medicine approach to the treatment of COPD, namely on identifying markers that predict which patients will benefit from specific treatments such as ICS. 11 One such predictor is peripheral blood eosinophilia, a biomarker that has been the subject of important recent advances in the context of the effectiveness of ICS. 4, 12, 13 One of the issues around the potential use of this biomarker is what cutoff value to use, with arguments on whether the threshold blood eosinophil count (measured as a percentage of total WBC count) should be > 2% or > 4% to predict which patients will benefit from ICS. 14, 15 In this editorial, we illustrate the importance of differentiating patients with COPD according to their potential benefit from ICS treatment by showing how the benefit-risk balance of ICS can be modified with such a precision medicine approach. We also evaluated the impact of using the two proposed blood eosinophil count cutoff values on this benefit-risk.
Illustration
Published sources of data from recent trials that were reanalyzed were used to evaluate the effects of blood eosinophil counts on ICS effectiveness. The primary source of data was two identical randomized trials that evaluated the effectiveness of a LABA-ICS combination (we selected mid-dose vilanterol with 100-mg fluticasone furoate) compared with the LABA only in reducing the incidence of COPD exacerbation over a 1-year followup. 16 A secondary source involves data from the Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management (WISDOM) trial in which patients with COPD were randomly allocated to continue or discontinue ICS use. 17 Both studies reevaluated the effects as a function of blood eosinophil counts. 18, 19 To provide a evenhanded benefit-risk assessment between effectiveness in reducing COPD exacerbation and safety from increasing pneumonia risk, we only considered the severe forms of these two outcomes, namely those leading to hospitalization. The first study was used to estimate the rates of severe exacerbation requiring hospitalization and of severe pneumonia for the LABA-ICS and LABA groups. The second study (ie, the WISDOM trial) was used to estimate the prevalence of different blood eosinophil counts and the corresponding approximate risk reductions for severe exacerbation according to blood eosinophil counts.
In the first study, after 1 year of follow-up, the 806 patients who received the LABA-ICS combination had a rate of severe exacerbation of 9% per year compared with 10% per year for the 818 receiving LABA only; the LABA-ICS-treated patients had a rate of severe pneumonia of 3% per year compared with 1% per year for those receiving LABA only. Table 1 displays these data rounded to 1,000 patients per group to simplify the presentation. In particular, it shows that for patients overall, the rate of severe pneumonia was increased by 2 per 100 patients per year with LABA-ICS treatment compared with LABA only, in contrast with the reduction in the rate of severe exacerbation of 1 per 100 patients per year with the LABA-ICS combination. Table 1 also describes two scenarios in which ICS are restricted to patients with two definitions of elevated blood eosinophil counts: > 2% and > 4%. In the analyses of the effects of ICS according to blood eosinophil counts at a threshold > 2% (which would include approximately 65% of all patients), the corresponding reduction in the incidence of COPD exacerbation is approximately 15% for this cutoff. 19 With a threshold of > 4% (about 20% of all patients), the reduction seems to be much more important (of the order of 50%). However, Table 1 also shows that the risk of severe pneumonia associated with ICS does not vary according to the blood eosinophil count.
13 Table 1 shows that among those with blood eosinophil counts > 2%, the reduction in the rate of severe exacerbation with the LABA-ICS combination is 1.5 per 100 patients per year; among those with counts > 4%, the reduction is 5 per 100 patients per year. The data also suggest that there is no difference in the rate of severe exacerbation between the two treatment arms among the remaining patients with low blood eosinophil counts.
Weighing the benefit of LABA-ICS on reducing the incidence of a severe COPD exacerbation against increasing the incidence of associated severe pneumonia, Table 1 shows that for every 100 typical patients with COPD, treatment with LABA-ICS instead of an LABA for 1 year will prevent one patient from having a severe COPD exacerbation leading to hospitalization but will induce two patients to develop severe pneumonia.
Conversely, Table 1 also shows that among responders to ICS, the benefit outweighs the risk, with LABA-ICS treatment preventing five patients from having a severe COPD exacerbation and inducing two patients to develop severe pneumonia (Fig 1) . However, among the nonresponders to ICS, risk clearly outweighs the absent benefit.
Applying these calculations to the US population of 12 million patients with COPD, one can estimate from survey data that approximately 8 million American patients are treated with ICS. Targeting the estimated 2 million who would respond meaningfully to these drugs according to the > 4% cutoff in blood eosinophil count, we can expect a reduction of 5 per 100 in the rate of hospitalization for COPD along with a 2 per 100 increase in hospitalization for pneumonia, for a net reduction in hospitalizations of 60,000 yearly. Furthermore, by avoiding ICS in the remaining 6 million who do not benefit from this drug, this targeted approach would prevent an estimated 120,000 patients from being hospitalized unnecessarily for pneumonia yearly.
Discussion
The longstanding debate regarding the use of ICS in the treatment of COPD was in part due to the rather modest degree of effectiveness observed in randomized controlled trials, along with the increased risk of pneumonia. 8, 9 There is now solid evidence that this modest finding was the result of a mix of effects due to the heterogeneity of COPD, namely an important benefit in the subset of patients who are responders to ICS and none in the nonresponders. In the spirit of a precision medicine approach, we showed that the identification of these patients is crucial to the benefitrisk balance of these drugs. Using the most recent findings on the role of blood eosinophil counts, we showed that with a threshold of > 4% to identify ICS responders, the benefit of treating with ICS in reducing the incidence of severe exacerbations outweighs the risk of severe pneumonia. However, among the non-ICS responders (< 4%), the risk outweighs the benefit, a result of the fact that the risk of pneumonia associated with ICS affects all patients equally, irrespective of the blood eosinophil count.
The advances in peripheral blood eosinophil research have provided a genuine precision medicine approach to chestjournal.org the treatment of COPD by identifying a biomarker that distinguishes patients who will benefit from a specific treatment, namely ICS. 4, 12, 14, 15 The discussion regarding the cutoff value to use for this biomarker is important because it will have an impact on a large number of patients. Indeed, a threshold > 2% in blood eosinophil counts will include approximately 65% of all patients with COPD, whereas a threshold > 4% will limit the use of ICS to approximately 20% of patients with COPD. 12, 18 We showed that although the threshold > 2% leads to a reduction in severe COPD exacerbations, the risk of severe pneumonia still outweighs the benefit at this threshold. Conversely, our calculations found that the threshold of > 4% leads to a greater reduction in severe COPD exacerbations than the corresponding increase in the risk of severe pneumonia, thus outweighing the risk by a net reduction of two hospitalizations per 100 patients treated with ICS per year.
To present a more comparable benefit-risk assessment of ICS use in relation to blood eosinophil counts, we focused exclusively on the severe forms of the outcomes; that is, COPD exacerbation and pneumonia leading to hospitalization. Most trials combine the moderate and severe COPD exacerbations in their analysis, making it difficult to balance benefit with risk of pneumonia when the latter is generally more severe. Indeed, although the moderate exacerbations (defined as worsening symptoms of COPD necessitating treatment with oral corticosteroids or antibiotics) are important, their severity is less than pneumonia. The severe COPD exacerbations represent approximately 10% of the combined moderate to severe exacerbations, whereas the severe pneumonias necessitating hospital admission represent about 30% to 40% of all reported pneumonias. 16 To obtain our estimates of benefit-risk, we had to combine data from two different studies to illustrate the benefit-risk calculations, as each study was limited in their presentation of either data on severe exacerbations, pneumonia, or the prevalence of different blood eosinophil counts. As a result, the data we used are quite approximate. More complete and extensive data on severe exacerbations in COPD trials would provide more accurate assessments of these calculations. In addition, research on methods that provide benefitrisk assessments comparing outcome events of varying severity would be welcome.
The recent research aiming to identify markers that predict which patients will benefit from ICS focused mainly on peripheral blood eosinophil counts, with several trial data reanalyzed to demonstrate the value of this biomarker. Other research has investigated the socalled asthma-COPD overlap syndrome, which is based on clinical characteristics that can allow clinicians to identify an asthma component in patients with COPD. These include the early onset of airway disease, such as a history of childhood asthma and a history of atopy, a normal diffusing capacity, and a large bronchodilator response. 10 A combination of these potential markers of ICS response could provide a more accurate identification of these patients and could also be the object of further research.
Conclusions
The excessive use of ICS in the treatment of COPD, currently estimated to be given to > 70% of patients, could be reduced to target those patients who would receive greater benefit than harm. For the estimated 8 million American patients with COPD treated with ICS, such a precision medicine approach could provide a net benefit to an estimated 2 million who respond to these drugs by reducing hospitalizations by 60,000 yearly. Furthermore, it would protect the remaining 6 million from the needless harms of these drugs in the absence of any or trivial benefit, preventing an estimated 120,000 patients from being hospitalized unnecessarily for pneumonia yearly. 
